Regeneron Pharmaceuticals, Inc. (REGN) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Regeneron Pharmaceuticals, Inc. (REGN) Bundle
Enhance your Regeneron Pharmaceuticals, Inc. (REGN) valuation analysis using our state-of-the-art DCF Calculator! This Excel template comes preloaded with real (REGN) data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Regeneron Pharmaceuticals, Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,863.4 | 8,497.1 | 16,071.7 | 12,172.9 | 13,117.2 | 14,436.6 | 15,888.7 | 17,486.9 | 19,245.8 | 21,181.7 |
| Revenue Growth, % | 0 | 8.06 | 89.14 | -24.26 | 7.76 | 10.06 | 10.06 | 10.06 | 10.06 | 10.06 |
| EBITDA | 2,420.1 | 3,900.5 | 9,281.0 | 5,335.4 | 4,693.3 | 6,180.0 | 6,801.6 | 7,485.7 | 8,238.7 | 9,067.4 |
| EBITDA, % | 30.78 | 45.9 | 57.75 | 43.83 | 35.78 | 42.81 | 42.81 | 42.81 | 42.81 | 42.81 |
| Depreciation | 210.3 | 235.9 | 286.2 | 341.4 | 421.0 | 382.4 | 420.9 | 463.2 | 509.8 | 561.1 |
| Depreciation, % | 2.67 | 2.78 | 1.78 | 2.8 | 3.21 | 2.65 | 2.65 | 2.65 | 2.65 | 2.65 |
| EBIT | 2,209.8 | 3,664.6 | 8,994.8 | 4,994.0 | 4,272.3 | 5,797.5 | 6,380.7 | 7,022.5 | 7,728.8 | 8,506.3 |
| EBIT, % | 28.1 | 43.13 | 55.97 | 41.03 | 32.57 | 40.16 | 40.16 | 40.16 | 40.16 | 40.16 |
| Total Cash | 6,471.1 | 6,722.6 | 12,532.7 | 14,334.1 | 10,844.8 | 12,186.4 | 13,412.2 | 14,761.3 | 16,246.1 | 17,880.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2,100.0 | 4,114.7 | 6,036.5 | 5,328.7 | 5,667.3 | 5,765.1 | 6,345.0 | 6,983.3 | 7,685.7 | 8,458.7 |
| Account Receivables, % | 26.71 | 48.42 | 37.56 | 43.78 | 43.21 | 39.93 | 39.93 | 39.93 | 39.93 | 39.93 |
| Inventories | 1,415.5 | 1,916.6 | 1,951.3 | 2,401.9 | 2,580.5 | 2,659.3 | 2,926.8 | 3,221.2 | 3,545.2 | 3,901.8 |
| Inventories, % | 18 | 22.56 | 12.14 | 19.73 | 19.67 | 18.42 | 18.42 | 18.42 | 18.42 | 18.42 |
| Accounts Payable | 418.1 | 475.5 | 564.0 | 589.2 | 606.6 | 689.7 | 759.1 | 835.4 | 919.5 | 1,011.9 |
| Accounts Payable, % | 5.32 | 5.6 | 3.51 | 4.84 | 4.62 | 4.78 | 4.78 | 4.78 | 4.78 | 4.78 |
| Capital Expenditure | -429.6 | -614.6 | -551.9 | -590.1 | -926.4 | -809.6 | -891.1 | -980.7 | -1,079.3 | -1,187.9 |
| Capital Expenditure, % | -5.46 | -7.23 | -3.43 | -4.85 | -7.06 | -5.61 | -5.61 | -5.61 | -5.61 | -5.61 |
| Tax Rate, % | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 |
| EBITAT | 1,924.8 | 3,378.8 | 7,788.7 | 4,459.1 | 4,022.3 | 5,210.0 | 5,734.1 | 6,310.9 | 6,945.6 | 7,644.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,391.9 | 541.7 | 5,655.0 | 4,492.8 | 3,017.1 | 4,689.3 | 4,485.9 | 4,937.2 | 5,433.8 | 5,980.3 |
| WACC, % | 5.34 | 5.35 | 5.34 | 5.35 | 5.36 | 5.35 | 5.35 | 5.35 | 5.35 | 5.35 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 21,735.9 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 6,160 | |||||||||
| Terminal Value | 262,233 | |||||||||
| Present Terminal Value | 202,086 | |||||||||
| Enterprise Value | 223,822 | |||||||||
| Net Debt | -27 | |||||||||
| Equity Value | 223,849 | |||||||||
| Diluted Shares Outstanding, MM | 114 | |||||||||
| Equity Value Per Share | 1,968.77 |
What You Will Get
- Comprehensive REGN Financials: Access both historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Regeneron's future performance.
- User-Friendly Interface: Designed for professionals but easy enough for newcomers to navigate.
Key Features
- Comprehensive DCF Calculator: Features in-depth unlevered and levered DCF valuation models tailored for Regeneron Pharmaceuticals, Inc. (REGN).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters specific to the biotech industry.
- Customizable Forecast Assumptions: Easily adjust growth rates, capital expenditures, and discount rates to fit Regeneron's financial outlook.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Regeneron Pharmaceuticals, Inc. (REGN).
- Interactive Dashboard and Charts: Visual representations of key valuation metrics facilitate straightforward analysis for investors.
How It Works
- Download: Get the comprehensive Excel file containing Regeneron Pharmaceuticals' financial data.
- Customize: Modify projections such as revenue growth, EBITDA %, and WACC to suit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Generate various forecasts and immediately compare the results.
- Make Decisions: Leverage the valuation insights to inform your investment choices.
Why Choose This Calculator?
- Accuracy: Utilizes real Regeneron financials for precise data.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive interface suitable for users without extensive financial modeling skills.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio management of Regeneron Pharmaceuticals, Inc. (REGN).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Regeneron Pharmaceuticals, Inc. (REGN).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain a deeper understanding of how biotech firms like Regeneron Pharmaceuticals, Inc. (REGN) are assessed in the market.
What the Template Contains
- Pre-Filled Data: Includes Regeneron Pharmaceuticals' historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Regeneron Pharmaceuticals' profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.